Semi-rigid linkers improve the pharmacokinetic properties and therapeutic efficacy of BET PROTACs for cancer therapy

Key Points

• Improved pharmacokinetic properties of BET PROTACs enhance their therapeutic efficacy in treating cancer.
• Key metrics show increased efficacy in cancer models, highlighting the advantages of semi-rigid linkers.
• The analysis examines the impact of linker structure on the pharmacokinetics of BET PROTACs in various models.
• These findings may enable better treatment strategies in cancer therapy, emphasizing the role of drug design.